PVRI 2025 exhibitors & sponsors

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

PHA’s mission is to extend and improve the lives of those affected by PH. To achieve this mission, PHA engages people with PH and their families, caregivers, health care providers, and researchers worldwide who work together to advocate for the PH community, provide support offer up-to-date education and information on PH, improve quality patient care, and fund and promote research.

At United Therapeutics, we partner with patients and healthcare providers to fight pulmonary hypertension and other lung diseases. Our research into promising pulmonary therapies has informed and shaped our long-term goal of an unlimited supply of transplantable organs. We are the first publicly traded biotechnology company organized to become a sustainable Public Benefit Corporation. We take our environmental, social, and governance responsibilities seriously, with core values that include safety, innovation, access, compliance, and ethics. Learn more at www.unither.com.

Chiesi is an international research-oriented biopharmaceutical group, with over 85-years of experience. We research, develop, and focus on innovative therapeutic solutions in respiratory health, rare diseases, and specialty care to improve the treatment of patients. Chiesi’s development pipeline consists of new molecular entities in areas such as asthma, COPD, bronchiectasis, and pulmonary fibrosis. Through our partnership with Gossamer Bio, and scientific societies such as PVRI, we continue to focus on innovative solutions for the management of patients with unmet medical needs in PAH and PH-ILD.

Pulmovant is a clinical-stage biotechnology company developing innovative therapies for patients suffering from pulmonary diseases. Pulmovant’s first program, mosliciguat is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is a novel, potential first-in-class, sGC activator with a differentiated mechanism that may have broad applicability across the PH spectrum.

For more information, please visit https://www.pulmovant.com.